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Abstract 
Background & Aims: Concerns persist about the risk of major congenital anomalies (MCA) in 
children of women with inflammatory bowel disease (IBD), and whether medication use affects risk. 
We assessed these risks, and variations in use of medications by women with IBD before, during, and 
after pregnancy. 
Methods: We accessed data on children born to women 15–45 y old from 1990 through 2010 using a 
mother–child linked dataset from an electronic database of primary care records containing medical 
diagnoses, events, and drug prescriptions from across the United Kingdom. We identified pregnant 
women with IBD and all prescriptions for 5-aminosalicylates, azathioprine/6-mercaptopurine, and 
corticosteroids were extracted from their primary care records. We calculated risks of MCA in children 
of mothers with and without IBD, and in children exposed or not exposed to 5-aminosalicylates, 
azathioprine/6-mercaptopurine, or corticosteroids during their first trimester of fetal development. 
Logistic regression with a generalized estimating equation was used to provide risk estimates 
adjusted for confounders. We calculated proportions of women taking medications before, during, and 
after pregnancy and assessed whether cessation was associated with subsequent disease flares. 
Results: Risks of MCA in 1703 children of mothers with and 384,811 children of mothers without IBD 
were 2.7% and 2.8% respectively. This corresponded to an adjusted odds ratio of 0.98 (95% 
confidence interval [CI], 0.73–1.31). In children of women with IBD, the adjusted odds ratios of MCA 
associated with drug use were 0.82 (95% CI, 0.42–1.61) for 5-aminosalicylates, 0.48 (95% CI, 0.15–
1.50) for corticosteroids, and 1.27 (95% CI, 0.48–3.39) for azathioprine/6-mercaptopurine. No 
increases in heart, limb, or genital anomalies were found in children of women with IBD; 31.2% of 
women discontinued 5-aminosalicylates and 24.6% discontinued azathioprine/6-mercaptopurine in 
early pregnancy. The risk of flares later in pregnancy was not related to cessation of medication. 
Conclusions: We found no evidence that IBD during pregnancy or medical therapy for IBD during 
pregnancy increases the risk of MCA in children. Patients should receive appropriate guidance on use 
of medication before and during pregnancy. 
KEYWORDS: Crohn’s disease; ulcerative colitis; birth defects; treatment 
3 
 
Introduction 
Inflammatory bowel disease (IBD) commonly affects women of reproductive age
1
, and is often 
managed using drugs recognised to have potential for toxicity in adults
2,3
. Since it is unethical to test 
the safety of almost all drugs in pregnancy in clinical trials, the potential for teratogenicity of drugs 
taken during pregnancy has been a pressing and natural concern of all pregnant women or those 
attempting to become so. This particularly affects women with chronic medical conditions that may 
only be effectively managed with medication. The risks of adverse effects in their children associated 
with the drugs taken during pregnancy continue to be a concern for women with IBD which has led to 
a number of studies in recent years
4–7
. However, IBD is a relatively uncommon condition and coupled 
with the rarity of individual congenital anomalies and mostly retrospectively collected data available to 
researchers, it remains unclear whether there is an overall increase in congenital anomalies among 
children born to women with IBD, and if so whether this is driven by medications. A meta-analysis 
published in 2007 showed that maternal IBD in pregnancy may be associated with an over 2-fold 
increased risk of congenital anomalies, which was more evident in women with ulcerative colitis (UC) 
than in women with Crohn’s disease (CD), however only 637 women with IBD across four studies 
were included
8
. A more recent population-based study assessing risks only in women with UC 
combined Danish and Swedish registry data and authors found no increased risk of congenital 
anomalies
9
. Both the meta-analysis and the later study, however, did not examine the effect of drug 
treatment separated from the effect of disease, nor the risks of system-specific congenital anomalies. 
In addition, the extent to which published studies include minor congenital anomalies is not clear, and 
their inclusion could increase the likelihood of ascertainment bias, thus inflating the risk of congenital 
anomalies in children born to mothers with IBD. 
The gestational safety of a number of commonly used drugs for IBD has been assessed and studies 
have not shown large or consistent increases in the occurrence of congenital anomalies
10–13
, but have 
nonetheless been unable to completely satisfy many of the safety of these drugs in pregnancy, 
particularly due to the small number of exposures included. Based on this evidence as well as the 
known tendency of IBD to flare upon cessation of disease suppressing medication and the recognised 
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excess of other adverse pregnancy outcomes which may be driven by disease activity
14
, a number of 
guidelines have been written
15–19
. These propose that women should not cease drug treatment that is 
maintaining their IBD in remission for the purpose of becoming pregnant or protecting a pregnancy, 
yet very recent studies indicate that women remain fearful of the potential harm of their drugs during 
pregnancy
20,21
. 
In view of the lack of certainty as to the risk of congenital anomalies in children born to women with 
IBD and among those taking suppressive medications, we have conducted a very large cohort study 
of pregnancies using United Kingdom (UK) primary care data. We set out to examine the hypotheses 
that maternal IBD per se is associated with an increased risk of major congenital anomaly and that 
corticosteroid, 5-aminosalicylic acid (5-ASA) and Azathioprine/6-Mercaptopurine use is associated 
with increased risks among women with IBD. Given the current lack of knowledge about how women 
and clinicians respond to perceived risks (in terms of drug use in pregnancy) despite existing 
guidelines, we also assessed prescribing patterns over a year before pregnancy, during and after 
pregnancy in detail and the extent to which cessation of treatment when pregnant was related to 
subsequent IBD flares in pregnancy. 
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Methods 
Defining the study population 
We studied all live singleton children born to women aged 15-45 years between 1990 and 2010 using 
an anonymised mother-child-linked dataset from The Health Improvement Network (THIN), a 
nationally representative UK database of primary care records containing medical diagnoses, events 
and drug prescriptions
22
. For each mother-child pair, we defined women as having IBD in pregnancy if 
they had a diagnosis of IBD ever before childbirth or if they had a diagnosis after childbirth but 
prescriptions of 5-ASA at some point before childbirth. Mothers with IBD were classified as having CD 
if they had diagnoses specifying this condition regardless of whether they also had diagnoses of UC, 
as having UC if they had recordings of UC but not CD, and as unclassified if their coding for IBD did 
not specify CD or UC. Among mothers with IBD, all prescriptions for 5-ASA, azathioprine/6-
Mercaptopurine or corticosteroids (including both oral and rectal corticosteroids) were extracted from 
their primary care electronic health records. Exposure in the first trimester was considered to occur if 
a prescription was issued between four weeks before a woman’s estimated conception date and 12 
weeks after. Beginning this period four weeks before conception enabled inclusion of drug 
prescriptions received immediately before pregnancy and potentially used in early pregnancy. 
Defining major and system-specific congenital anomalies 
All diagnoses of major congenital anomalies were identified in the children’s medical records using 
Read codes, classified into system-specific groups according to the European Surveillance of 
Congenital Malformations (EUROCAT) subgroups
23
. These subgroups are defined using International 
Classification of Diseases (ICD-10) codes to which our coding was mapped. Children with records of 
genetic anomalies attributed to known teratogens (such as Read codes for anomalies due to maternal 
infections and foetal alcohol syndrome) were excluded, comprising less than 0.1% of the original child 
population. 
Defining maternal co-variables 
We extracted data on the following maternal characteristics: maternal age at childbirth, calendar year 
of childbirth (categorised as 1990-1996, 1997-2003 and 2004-2010), maternal smoking status and 
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socioeconomic deprivation measured using the Townsend Index of Deprivation, in quintiles
24
. 
Maternal smoking status was defined using women’s most recent smoking status before childbirth, 
categorised as non-smoker, current smoker, ex-smoker and unknown. 
Statistical analyses 
We calculated absolute risks (per 10,000 live births) of all major congenital anomalies and anomalies 
in 14 system-specific groups for children born to women without IBD, women with any type of IBD and 
women with CD or UC separately. Since there were only 104 women with unclassified IBD, we did not 
separately assess this group. Logistic regression was used to estimate odds ratios (ORs) with 95% 
confidence intervals (95%CIs) for the association of any major congenital anomaly and the three most 
common system-specific subgroups (heart, limb and genital anomalies) in children born to mothers 
with IBD compared to those born to mothers without IBD who acted as controls, with full adjustment 
for co-variables.   
Among women with IBD, we calculated the proportions of children exposed to 5-ASA, corticosteroids 
or Azathioprine/6-Mercaptopurine in the first trimester of pregnancy and used logistic regression to 
assess the association of each type of antenatal drug exposure with the risks of major congenital 
anomalies. Because prescriptions for Azathioprine and 6-Mercaptopurine are commonly for long 
periods, we additionally conducted a sensitivity analysis using an extended antenatal exposure 
window beginning at 12 (instead of four) weeks before conception. For all regression analyses the 
generalised estimating equation approach with exchangeable correlation structure was applied to 
control for potential clustering effects when children were born to the same woman in consecutive 
pregnancies. 
To examine the extent to which women and physicians may modify IBD drug treatment in relation to 
pregnancy, we calculated the proportions of children exposed to Azathioprine/6-Mercaptopurine in 
each trimester of pregnancy and in 3-month periods extending to 15 months before and after 
pregnancy. We also assessed whether women who were on drug treatment in the 9 months before 
pregnancy continued or discontinued drug treatment in the first trimester of pregnancy and the 
occurrence of flares (defined using prescriptions of oral and rectal corticosteroids) in the second and 
third trimesters of pregnancy and also in the 9 months postpartum. We additionally subdivided the 
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analysis by disease type and presented the results for UC and CD separately. All analyses were 
carried out using Stata SE 11.0 (Stata Corp., TX, USA). 
Ethical approval for this research was obtained from the South-East Multicentre Research Ethics 
Committee (SE-REC) reference 04/MRE01/9. 
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Results 
Of 386,514 children, 0.4% were born to mothers who had IBD before childbirth (n=1,703) and 0.2% to 
mothers with CD (n=893). Table 1 shows maternal characteristics for children born to women with and 
without IBD. Compared with children in the control group, children in the IBD group were less likely to 
be from socioeconomically deprived areas, were more likely to be born later in the study period and 
their mothers were slightly older (Table 1). However, children born to women with CD were more likely 
to be from socioeconomically deprived areas and their mothers were more likely to be current 
smokers compared with children born to women with UC (Table 1). 
Absolute and relative risks of major congenital anomalies with IBD 
Tables 2 and 3 show the absolute and relative risks of any major congenital anomaly and system-
specific anomalies in children born to women with IBD compared with children in the control group. 
The overall prevalence of any major congenital anomaly was 2.7% in children born to women with 
IBD, 3.7% in children born to women with UC, 1.9% in children born to women with CD, and 2.8% in 
in the control group (adjusted ORs=0.98 [95%CI 0.73-1.31] for IBD overall, 1.34 [95%CI 0.91-1.97] for 
UC, and 0.68 [95%CI 0.41-1.13] for CD). For system-specific anomalies, there were variations in 
absolute risks across groups with no consistent increases or decreases (Table 2). All 95%CIs of ORs 
included unity (Table 3). 
Risks of major congenital anomalies with drug treatment for IBD 
The proportions of children exposed to 5-ASA in the first trimester were 32.4% in children born to 
women with IBD, 40.9% in children born to women with UC, and 28.6% for CD (Table 4). Exposure to 
corticosteroids was similar for women with UC and CD whereas women with CD were more likely to 
be exposed to Azathioprine/6-Mercaptopurine in early pregnancy than women with UC (Table 4). 
Table 5 shows the relative risks of any major congenital anomaly and system-specific groups (heart, 
limb and genital system) in children exposed to 5-ASA, corticosteroids or Azathioprine/6-
Mercaptopurine in the first trimester of pregnancy compared with children born to women with IBD but 
not prescribed the respective drugs. All 95% CIs of adjusted ORs included unity (Table 5). The ORs 
for Azathioprine/6-Mercaptopurine were similar in the sensitivity analysis which included prescriptions 
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12 weeks before to 12 weeks after conception (adjusted OR=1.50, 95%CI 0.79-2.84 for any major 
congenital anomaly). 
Changes in preconception, antenatal and postnatal medication use 
Figure 1 shows that in 1,162 women with IBD who were registered with their GP throughout the 15 
months before pregnancy, during pregnancy and in 15 months postpartum, the proportions of women 
prescribed Azathioprine/6-Mercaptopurine decreased shortly before conception and generally 
continued decreasing throughout pregnancy, particularly for women with CD. In the post-partum 
period, prescribing prevalence rose again to a similar level to that in the months before conception 
(Figure 1). 
Going on to assess the occurrence of flares of disease in relation to changes in drug use, we found 
that in 487 women who were prescribed 5-ASA in the 9 months before pregnancy (Figure 2a), 68.8% 
(335) of them had another prescription in the first trimester of pregnancy, of whom 56 (16.7%) had a 
flare later in pregnancy and 57 (17.0%) had a flare postpartum; however in the remaining 152 women 
who discontinued their medication in early pregnancy 18.4% had a flare later in pregnancy and 11.2% 
had a flare postpartum. Among 122 women prescribed Azathioprine/6-Mercaptopurine in the 9 
months before pregnancy (Figure 2a), 75.4% (92) of them continued on medication when pregnant, of 
whom 8.7% and 13.0% developed a subsequent flare in later pregnancy and postpartum respectively. 
Of the 30 women who discontinued Azathioprine/6-Mercaptopurine use in pregnancy 10.0% had a 
flare later in pregnancy and another 10.0% had a flare in the 9-month postpartum period. For neither 
drug was the proportion of women experiencing a flare significantly different between those ceasing 
and continuing the drug (p=0.65 and 0.17 for 5-ASA discontinuation and p=0.83 and 0.93 for 
Azathioprine/6-Mercaptopurine discontinuation with flares in later pregnancy and postpartum 
respectively). Similar figures subdivided between Crohn's disease and UC are given in figures 2b and 
2c demonstrating a higher overall rate of flare in UC. Due to inadequate power statistical testing of the 
effect of drug cessation on flares was not conducted in the subdivided analysis. 
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Discussion 
Principal findings 
This study is among the largest in terms of numbers of women with IBD included, numbers of births 
and numbers of major congenital anomalies which has yet been conducted to assess risks of 
congenital anomalies among the children of women with IBD. It has demonstrated no overall excess 
risk of major congenital anomaly in children born to mothers with IBD and none associated with 
Azathioprine/6-Mercaptopurine, corticosteroids or 5-ASA use within the maternal IBD population. The 
study has also been able to describe how women vary their use of medication for IBD around the time 
of pregnancy in order to assess not only whether they are stopping 5-ASA and Azathioprine/6-
Mercaptopurine, but also whether doing so is associated with increased use of corticosteroids (as a 
proxy for flares of IBD) during pregnancy. We have found that an appreciable proportion (between 25 
and 31%) of women stop receiving prescriptions, but this was not associated with a significant 
increase in flares later in pregnancy. 
Strengths and limitations  
Besides its size and consequent precision, our study has a number of other advantages. As the 
selection of both cases and controls is truly population based, and the ascertainment of outcomes is 
independent of a pre-designed research protocol (since we are using routinely collected data), we 
have minimised the opportunities for selection and ascertainment bias beyond that which occurs 
routinely in clinical practice. In addition, the availability of contemporaneously gathered prescription 
data provides us the opportunity to examine drug effects, and data on maternal smoking, 
socioeconomic status and maternal age allow us to correct for some important potential confounders. 
Our methodology of course also has limitations. Though our study is large, due to the rarity of 
outcomes, the power is still limited. We are for example arguably underpowered to compare the risks 
of congenital anomalies between UC and Crohn's and are underpowered to investigate most 
individual anomalies. Also since we have used anonymised routinely collected records, we have been 
unable to go back to the patients or their paper records to validate the information we have used. As 
regards our exposure data, the diagnosis of IBD has been previously validated in UK electronic 
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general practice records and found to be highly reliable
25
, and prescriptions are automatically entered 
at the point of issue on the database such that error in their measurement will be minimal. The 
diagnosis of our congenital anomaly outcome in electronic primary care data has also been validated 
against written primary care records
26
. Furthermore, prevalence estimates across all system-specific 
groups and for specific major congenital anomaly diagnoses are comparable to those reported in UK 
registers of the European Surveillance of Congenital Anomalies network
27
 and in the case of trisomy 
21 the expected variation by age is shown
28
. Our inability to individually check children however might 
still permit a bias to arise if, for example, the children born to women with IBD are more carefully 
assessed. This bias would of course be one to which essentially all previous studies have been 
susceptible, and would bias towards finding an association with congenital abnormalities which we did 
not detect. Unlike most previous studies in this field
7,10,29–33
 we have tried to minimise ascertainment 
bias of this type by limiting our analysis to major congenital anomalies which are unlikely to go 
undetected in the offspring of healthy mothers. 
Interpretation in the context of previous literature  
Recent US data from a large prospective study as yet reported in abstract only (the PIANO study) are 
in general in keeping with our findings that thiopurines are not associated with increased congenital 
anomalies
34
. The previous literature on congenital anomalies and IBD is however plagued by studies 
with limited power. Though a meta-analysis was conducted in 2007 to attempt to overcome this and 
found an excess of congenital anomalies in children born to women with IBD (OR=2.37, 95%CI 1.47-
3.82), more evident in UC (OR=3.88, 95%CI 1.41-10.67) than in CD (OR=2.14, 95%CI 0.97-4.74)
8
, it 
included only five studies with 702 pregnancies in total, which reduced to only 539 once the three 
smallest studies
30,33,35
 (<100 pregnancies in women with IBD) had been excluded. The estimates 
from the meta-analysis are therefore driven by three studies
29,35,36
, but these among them studied 
only about one third of the pregnancies exposed to IBD presented in our current paper and half the 
number reported in the PIANO study . Although a large population-based study published in 2011 
using both Danish and Swedish registry data
9
 included 84 congenital anomalies in children born to 
women with UC and found no increased risk of congenital anomalies (OR=1.05, 95%CI 0.84-1.31), 
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this later study compared only UC patients with all other non-UC patients and did not assess potential 
drug exposures or diagnoses of CD
9
. When considering the difference between our results and these 
previous studies it is also important to note that like our study they were reliant upon clinical 
databases for their information, and though the Danish and Swedish study excluded some minor 
congenital anomalies, they did not limit analysis to major anomalies alone and so may have been 
more vulnerable to bias in the ascertainment of anomalies than in the current study.  
Perhaps more important than the risk of congenital anomalies from merely having IBD, which women 
cannot prevent, is the risk related to drug exposures which they may be able to alter. In this regard 
our results are broadly consistent with the previous literature
11–13
, showing no excess risk related to 
the use of 5-ASA, corticosteroids or Azathioprine/6-Mercaptopurine. Of course once we begin 
studying small subgroups such as that of women treated in pregnancy with specific drugs, the power 
of our study is greatly reduced. This somewhat limits the comfort provided by for example our 
estimate of a non-significant reduction in congenital anomalies in children born to mothers who took 
5-ASA during pregnancy (OR=0.82, 95%CI 0.42-1.61). The idea that no significant excess risk from 
the use of these drugs exists, is however supported by a 2008 meta-analysis which found no 
statistically significant excess of congenital anomalies and a point estimate of a 1.16-fold excess risk 
for 5-ASA exposure
11
. A similar situation exists for Azathioprine/6-Mercaptopurine, in which a recent 
meta-analysis on the effects of thiopurines on birth outcomes in patients with IBD found a non-
significant excess of risk of congenital anomalies and an OR of 1.45 (95%CI 0.99-2.13)
13
. The 
situation is slightly different for corticosteroids where the most recent available meta-analysis, though 
it does not show an overall risk of any MCA, does suggest an excess of cleft lip and palate
12
 which we 
lack power to assess even to the extent which we have examined the overall risk.  
Based upon the existing literature there is a near uniformity of recommendations on the use of IBD 
medications in pregnancy
15,19
. Though it is recommended that methotrexate should not be used in 
pregnancy
37
, for 5-ASA, Azathioprine/6-Mercaptopurine and short term administration of 
corticosteroids, the risks of disease if their use is prevented is thought to outweigh the risks to the 
mother and foetus of continuing the medication
15
. How well this message has been communicated to 
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patients, and to what extent the advice is acted upon has however been little studied. Previous 
research conducted in Australia showed that women with IBD were fearful of the effects of medication 
upon pregnancy with 30% specifically fearing congenital anomalies
38
 and as many as 84% fearing 
some adverse effect upon the pregnancy
14
. We also have data from Denmark where studies in UC 
and CD have demonstrated that not only do women with IBD fear the effects of their medications, but 
this also leads to reduced adherence
20,21
. Since all of these studies were based upon questionnaires, 
and therefore are susceptible both to recall and response biases, the data they provided on 
medication usage by women with IBD during pregnancy may be less reliable than the prospectively 
recorded prescription data which we have analysed despite the fact that we are unable to assess 
compliance. These studies are also unable to help us judge to what extent non-compliance with 
medication during pregnancy may have been associated with changes in disease activity. The current 
study, though it can tell us nothing of the reasons for women's choices or of their fears, can help fill in 
some of these gaps. We have shown that about 3/4 of women taking 5-ASA or Azathioprine/6-
Mercaptopurine prior to pregnancy continue to do so during pregnancy, but that about 1/4 cease to 
receive prescriptions (and therefore presumably stop). If we accept the use of corticosteroid 
prescriptions as a proxy for disease activity (as previously validated in UK primary care data by Lewis 
et al
39
), then the analysis we present in Figure 2 shows only a  slight non-significant increase in the 
proportion of women who have flares following the cessation of 5-ASA and Azathioprine/6-
Mercaptopurine in early pregnancy. When interpreting this finding though it may be instructive to 
consider the likely scenario in which medications are stopped. Women will be less likely to stop their 
medication if they have symptomatic (even mildly symptomatic) disease, and so it is likely that those 
who stopped were at the time of cessation on average suffering less from disease activity than those 
who continued taking medication. In this context a small albeit not statistically significant increase in 
flares in those stopping 5-ASA or Azathioprine/6-Mercaptopurine may well signal that the effect of 
cessation in pregnancy is the same as that outside it, and promotes increased flares
40
. 
Conclusion 
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We conclude that neither IBD, nor its common medical treatments are likely to be major risk factors 
for congenital anomalies, but that this message may not have reached all pregnant women. About 
one quarter of women stop their medication in pregnancy. Though this may increase the risk of flares 
later in pregnancy, we were unable to demonstrate such increase.
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Table 1 Characteristics of pregnancies of women with and without IBD before childbirth (N=386,514) 
 Controls All IBD* UC CD 
n=384,811 n=1,703 n=706 n=893 
n % n % n % n % 
Maternal age at childbirth, years       
Mean (SD) 29 (5.7) 31 (4.9) 32 (4.6) 31 (5.1) 
Year of childbirth        
1990-1996 73,951 19.2 214 12.6 83 11.8 117 13.1 
1997-2003 142,320 37.0 601 35.3 246 34.8 320 35.8 
2004-2010 168,540 43.8 888 52.1 377 53.4 456 51.1 
Townsend deprivation index       
1 (Least deprived) 92,359 24.0 511 30.0 225 31.9 250 28.0 
2 73,258 19.0 368 21.6 160 22.7 180 20.2 
3 74,083 19.3 311 18.3 145 20.5 149 16.7 
4 69,601 18.1 241 14.2 92 13.0 140 15.7 
5 (Most deprived) 51,997 13.5 174 10.2 50 7.1 116 13.0 
Missing 23,513 6.1 98 5.8 34 4.8 58 6.5 
Maternal smoking status        
Non-smoking 101,664 26.4 499 29.3 261 37.0 206 23.1 
Ex-smoking 127,528 33.1 618 36.3 276 39.1 306 34.3 
Current smoking 55,279 14.4 240 14.1 53 7.5 170 19.0 
Missing 100,340 26.1 346 20.3 116 16.4 211 23.6 
*104 pregnancies of women had unclassified IBD 
IBD=Inflammatory bowel disease; UC=ulcerative colitis; CD=Crohn's disease 
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Table 2 Absolute risks of major congenital anomalies and system-specific congenital anomalies in 
children born to women with and without IBD before childbirth (N=386,514) 
 Controls All IBD UC CD 
n=384,811 n=1,703 n=706 n=893 
n n/10,000 n n/10,000 n n/10,000 n n/10,000 
Any major congenital anomalies 10,645 277 46 270 26 368 17 190 
Heart 3,032 79 17 100 9 128 7 78 
Limb 2,059 54 5 29 4 57 1 11 
Genital system 1,542 40 8 47 4 57 2 22 
Urinary system 1,004 26 3 18 0 - 3 34 
Chromosomal 699 18 2 12 2 28 0 - 
Oro-facial cleft 529 14 3 18 1 14 2 22 
Nervous system  596 16 4 24 2 28 2 22 
Musculoskeletal system 515 13 2 12 2 28 0 - 
Digestive system 397 10 2 12 2 28 0 - 
Eye 388 10 0 - 0 - 0 - 
Other malformations* 375 10 0 - 0 - 0 - 
Respiratory system 253 7 2 12 1 14 1 11 
Ear, face and neck 103 3 1 6 1 14 0 - 
Abdominal wall 92 2 0 - 0 - 0 - 
IBD=Inflammatory bowel disease; UC=ulcerative colitis; CD=Crohn's disease 
* e.g. asplenia, situs inversus, and skin disorders 
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Table 3 Adjusted odds ratios for the association of maternal IBD with any major and system-specific 
congenital anomalies in children 
 All IBD UC  CD  
AOR* 95%CI AOR* 95%CI AOR* 95%CI 
Any major congenital anomaly 0.98 0.73-1.31 1.34 0.91-1.97 0.68 0.41-1.13 
Heart 1.24 0.75-2.05 1.59 0.82-3.05 0.97 0.42-2.24 
Limb 0.55 0.23-1.33 1.05 0.39-2.81 0.21 0.03-1.50 
Genital system 1.19 0.59-2.39 1.43 0.53-3.84 0.57 0.14-2.26 
*Odds ratios adjusted for maternal age in three categories, calendar year period of childbirth, Townsend Deprivation Index and 
maternal smoking status 
OR=odds ratio; 95%CI=95% confidence interval 
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Table 4 Numbers and proportions of 5-ASA, corticosteroids and Azathioprine/6-Mercaptopurine 
prescribed in the first trimester of pregnancy* for women with IBD 
 All IBD UC CD 
n=1,703 n=706 n=893 
n % n % n % 
5-ASA 551 32.4 289 40.9 255 28.6 
Steroids 209 12.3 98 13.9 108 12.1 
Azathioprine/6-
Mercaptopurine 
149 8.7 34 4.8 115 12.9 
*defined as from 4 weeks before to 12 weeks after conception 
5-ASA=5-aminosalicylic acid; IBD=Inflammatory bowel disease; UC=ulcerative colitis; CD=Crohn's disease 
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Table 5 Adjusted odds ratios for the risk of major congenital anomalies in children of women with IBD 
prescribed 5-ASA, steroid or azathioprine in the first trimester, compared with those of women with 
IBD not given that drug (N=1,703) 
 Major congenital anomalies 
 n n/10,000 Adjusted OR* (95%CI) 
5-ASA (n=551)    
Any major congenital anomalies 13 236 0.82 (0.42-1.61) 
Heart 4 73 0.66 (0.18-2.48) 
Limb 2 36 1.40 (0.18-11.02) 
Genital system 2 36 0.71 (0.15-3.35) 
Corticosteroids (n=209)    
Any major congenital anomalies 3 144 0.48 (0.15-1.50) 
Heart 2 96 0.99 (0.22-4.39) 
Limb 0 0 --- 
Genital system 1 48 0.91 (0.13-6.20) 
Azathioprine/6-Mercaptopurine ^ 
(n=149) 
   
Any major congenital anomalies 5 336 1.27 (0.48-3.39) 
Heart 2 134 1.56 (0.29-8.26) 
Limb 0 0 --- 
Genital system 2 134 3.37 (0.64-17.73) 
*ORs adjusted for maternal age in three categories, calendar year period of childbirth, Townsend Deprivation Index and 
maternal smoking status 
^ The results are similar after assessing women prescribed azathioprine 12 weeks before or after conception. 
OR=odds ratio; 95%CI=95% confidence interval; 5-ASA=5-aminosalicylic acid 
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Figure Legends 
 
Figure 1 Percentages of women prescribed Azathioprine/6-Mercaptopurine in the 15 months before 
pregnancy, during pregnancy and in the 15 months after childbirth in women with IBD (N=1,162 
women registered with their GP throughout this period) 
Figure 2 The changes in prescriptions of 5-aminosalicylic acid and Azathioprine/6-Mercaptopurine in 
women before pregnancy and in the first trimester and the number of flares later in pregnancy and 
postpartum. a) All IBD. b) Crohn's disease. c) UC 
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Figure 2a Prescriptions of 5-aminosalicylic acid and Azathioptine/6-Mercaptopurine in women with 
IBD before pregnancy and in the first trimester and the number of flares later in pregnancy and 
postpartum 
 
 
 
 
 
 
 
 
Figure 2b Prescriptions of 5-aminosalicylic acid and Azathioptine/6-Mercaptopurine in women with CD 
before pregnancy and in the first trimester and the number of flares later in pregnancy and postpartum 
 
 
 
 
 
 
 
 
Figure 2c Prescriptions of 5-aminosalicylic acid and Azathioptine/6-Mercaptopurine in women with UC 
before pregnancy and in the first trimester and the number of flares later in pregnancy and postpartum 
 
n=56 (16.7%) n=28 (18.4%) n=8 (8.7%) n=3 (10.0%) 
n=17 (11.2%) n=57 (17.0%) n=12 (13.0%) n=3 (10.0%) 
n=335 (68.8%) n=152 (31.2%) n=92 (75.4%) n=30 (24.6%) 
Continued Continued 
Discontinued Discontinued 
n=487 n=122 
5-aminosalicylic acid Azathioprine 
Flare in later pregnancy 
Taken in 9-month before pregnancy 
Taken in 1
st
 trimester of pregnancy 
Flare in the 9-month postpartum 
but not in later pregnancy 
n=9 (12.7%) n=24 (15.8%) n=7 (9.5%) n=3 (12.5%) 
n=152 (68.2%) n=71 (31.8%) n=74 (75.5%) n=24 (24.5%) 
Continued Continued Discontinued Discontinued 
n=223 n=98 
5-aminosalicylic acid Azathioprine 
Flare in later pregnancy 
Taken in 9-month before pregnancy 
Taken in 1
st
 trimester of pregnancy 
Flare in the 9-month postpartum 
but not in later pregnancy 
n=17 (11.2%) n=6 (8.5%) n=3 (4.1%) n=2 (8.3%) 
n=8 (10.7%) n=32 (18.1%) n=5 (27.8%) n=0 
n=177 (70.2%) n=75 (29.8%) n=18 (75.0%) n=6 (25.0%) 
Continued Continued Discontinued Discontinued 
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5-aminosalicylic acid Azathioprine 
Flare in later pregnancy 
Taken in 9-month before pregnancy 
Taken in 1
st
 trimester of pregnancy 
Flare in the 9-month postpartum 
but not in later pregnancy 
n=39 (22.0%) n=22 (29.3%) n=5 (27.8%) n=1 (16.7%) 
